title: Development and validation of a direct enantiomeric separation of pregabalin to support isolated perfused rat kidney studies.
abstract: Pregabalin (Lyrica) is the first compound approved to treat the neural pain associated with fibromyalgia. Pregabalin is the S-enantiomer of a gamma-amino acid analogue and chiral separation from its R-enantiomer must be achieved to support metabolic studies. The direct chiral separation of pregabalin from its R-enantiomer has been developed and HPLC/MS/MS assays have been validated to support isolated perfused rat kidney studies. The separation was developed through serial coupling of various macrocyclic glycopeptide stationary phases until partial separation of the enantiomers was achieved. Identification of the resolving stationary phase followed by optimization of the mobile phase enabled the baseline resolution of the enantiomers using mass spectrometry compatible solvents and modifiers. Assays were developed and validated for quantitation of the enantiomers from rat urine, isolated rat kidney perfusate, and isolated rat kidney perfusate ultrafiltrate to support pregabalin metabolic studies.
authors.affiliation: Pharmacokinetics, Dynamics & Metabolism, Pfizer Global Research and Development, Pfizer Inc., Ann Arbor, MI 48105, USA. yizhong.zhang@pfizer.com
authors.forename: Yizhong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Christopher
authors.initials: C
authors.lastname: Holliman
authors.forename: Daniel
authors.initials: D
authors.lastname: Tang
authors.forename: Douglas
authors.initials: D
authors.lastname: Fast
authors.forename: Steven
authors.initials: S
authors.lastname: Michael